-
PhaseBio's IPO: What You Need To Know
Wednesday, October 17, 2018 - 1:19pm | 396Read More...Clinical-stage biopharmaceutical company PhaseBio recently filed for an initial public offering. The stock is expected to trade on the Nasdaq Global Market under the ticker symbol “PHAS.” The Company Founded in 2002, PhaseBio develops and researches treatments for orphan cardiopulmonary...
-
Why Raymond James Is Bullish On Deciphera, Dova Pharmaceuticals
Wednesday, August 29, 2018 - 2:19pm | 652Read More...Raymond James launched coverage of two pharmaceutical names Tuesday afternoon with bullish ratings. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) is a clinical-stage biopharmaceutical company that addresses key mechanisms of tumor drug resistance. Dova Pharmaceuticals Inc (NASDAQ: DOVA)...
-
Adamis Pharma Soars 60% Amid New Partnership With Novartis To Commercialize Symjepi
Monday, July 2, 2018 - 10:14am | 373Read More...Shares of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) soared higher by 60 percent early Monday morning in reaction to a new partnership with Novartis AG (ADR) (NYSE: NVS). What Happened Adamis, a specialty biopharmaceutical company that focuses on treatments for respiratory diseases and...
-
Verastem Shares Hit Highest Level Since 2015 On Duvelisib Data
Monday, June 18, 2018 - 11:09am | 359Read More...Verastem Inc (NASDAQ: VSTM) shares gained 20 percent Monday morning and traded above the $7 per share mark for the first time since 2015 in reaction to an encouraging presentation delivered over the weekend. What Happened Versatem presented encouraging results from its lead candidate...
-
Emergent Biosolutions' Stock Run Can't Continue Forever, Wells Fargo Says In Downgrade
Wednesday, April 25, 2018 - 3:38pm | 340Read More...Specialty biopharma Emergent Biosolutions Inc (NYSE: EBS) has seen its stock rise more than 40 percent over the past two years, and investors shouldn't expect to see such outsized returns going forward, according to Wells Fargo. The Analyst Wells Fargo's David Maris downgraded...
-
HC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly Fivefold
Friday, April 6, 2018 - 2:43pm | 343Read More...Palatin Technologies, Inc. (NYSE: PTN), a biopharmaceutical company that focuses on treatments for diseases with significant unmet medical needs, boasts a lead asset, bremelanotide, that has an "arousing number of major boxes checked," according to H.C. Wainwright. The Analyst H.C....
-
What's The Thesis On ProQR Now, After Promising Phase 1 Data?
Tuesday, September 26, 2017 - 11:41am | 377Read More...ProQR Therapeutics NV (NASDAQ: PRQR), a nano-cap pre-clinical stage bio pharmaceutical company engaged in the discovery and development of ribonucleic acid-based therapeutics for the treatment of severe genetic disorders, announced the completion of a phase 1b study Monday, which helped boost...
-
Alnylam Pharmaceutical Surges After Rare Disease Drug Met Key Endpoints
Wednesday, September 20, 2017 - 8:25am | 415Read More...Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) surged higher by more than 20 percent early Wednesday morning after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through...
-
INC Research Confirms Completion Of Merger With InVentiv Health
Tuesday, August 1, 2017 - 10:46am | 452Read More...INC Research Holdings Inc (NASDAQ: INCR) confirmed Tuesday its merger with inVentiv Health, Inc. has closed. The former is a global contract research organization that focuses on phase 1 through 4 clinical development services for the biopharmaceutical and medical device industries, while the...
-
Here's Why Shares Of Intercept Jumped Nearly 10% On Friday
Friday, February 10, 2017 - 10:47am | 355Read More...Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) jumped nearly 10 percent early Friday morning after the company provided an update on an ongoing clinical trial. Intercept is a biopharmaceutical company that focuses on developing and commercializing therapeutics to treat progressive non-viral...
-
AEterna Zentraris Surged 17%: Here Is What You Need To Know
Monday, January 25, 2016 - 2:27pm | 228Read More...Shares of AEterna Zentaris Inc. (NASDAQ: AEZS), a specialty nano-cap bio-pharmaceutical company engaged in developing treatments in oncology, endocrinology and women's health, surged higher by more than 17 percent on Monday after the company confirmed that several of its executive managers...
-
Here's Why Shares Of Onco Genex Pharma Are Plunging
Thursday, January 21, 2016 - 10:28am | 172Read More...Shares of OncoGenex Pharmaceuticals Inc (NASDAQ: OGXI), a nano-cap and clinical-stage biopharmaceutical company, were trading lower by nearly 25 percent at $0.580 early Thursday morning. OncoGenex Pharmaceuticals announced after Wednesday's market close that data from its Phase 2 Spruce trial which...
-
Acorda Therapeutics To Acquire Biotie Therapies To Boost Its Parkinson's Disease Therapeutic Development
Tuesday, January 19, 2016 - 10:40am | 322Read More...Acorda Therapeutics Inc (NASDAQ: ACOR), a biopharmaceutical company that develops therapies for neurological disorders, on Tuesday announced that it has acquired Biotie Therapies Oyj (ADR) (NASDAQ: BITI) for $25.60 per ADS. Biotie Therapies is a Finland-based drug development company...
-
Shares Of Auris Medical Continue Surging On No News
Wednesday, January 6, 2016 - 12:50pm | 185Read More...Shares of Auris Medical Holding Ag (NASDAQ: EARS), a development-stage biopharmaceutical company, were trading higher by more than 20 percent at $7.17 late Wednesday morning. Auris Medical's stock is now trading higher by over 40 percent over the past five trading days and are higher by...
-
Conatus Pharmaceuticals Surges 25% Following Positive Results In Phase 2 Study
Wednesday, January 6, 2016 - 9:45am | 300Read More...Shares of Conatus Pharmaceuticals Inc (NASDAQ: CNAT), a small-cap biopharmaceutical company focused on developing medicines to treat liver diseases, were trading higher by 25 percent at $3.61 early Wednesday morning. Conatus Pharmaceuticals announced after Tuesday's market close that a three-month...
